Abstract：
OBJECTIVE: Previous research showed that ALG3 was associated with several cancers, but the function of ALG3 in bladder cancer (BC) was yet unknown. The purpose of this study was to investigate the relative expression of ALG3 in BC tissues and corresponding normal tissues and the relationship between the relative expression of ALG3 and clinical outcome in bladder cancer patients.
METHODS: In this study, the expression of ALG3 in bladder cancer was detected by immunochemistry. In order to determine the cell proliferation and migration ability more accurately, we performed colony forming assay, MTT assay and wound healing migration assay. The role of ALG3 on tumor growth and metastasis was explored by animal model in vivo.
RESULTS: ALG3 was expressed higher in bladder cancer than that in the normal tissues (P<0.05). At the same time, we found that there was a positive correlation between ALG3 expression and the prognosis (P<0.05). Moreover, we also discovered that the expression of ALG3 was associated with clinical pathological features (P<0.05). The proliferation and migration abilities of bladder cancer cell line T24 and 5637 were inhibited by silencing ALG3. In addition, the growth of bladder cancer cell line T24 cells were inhibited by silencing ALG3 in vivo.
CONCLUSIONS: Silencing ALG3 plays a critical role in bladder cancer development and growth. It inhibits bladder cancer cells growth in vitro and in vivo.
METHODS: In this study, the expression of ALG3 in bladder cancer was detected by immunochemistry. In order to determine the cell proliferation and migration ability more accurately, we performed colony forming assay, MTT assay and wound healing migration assay. The role of ALG3 on tumor growth and metastasis was explored by animal model in vivo.
RESULTS: ALG3 was expressed higher in bladder cancer than that in the normal tissues (P<0.05). At the same time, we found that there was a positive correlation between ALG3 expression and the prognosis (P<0.05). Moreover, we also discovered that the expression of ALG3 was associated with clinical pathological features (P<0.05). The proliferation and migration abilities of bladder cancer cell line T24 and 5637 were inhibited by silencing ALG3. In addition, the growth of bladder cancer cell line T24 cells were inhibited by silencing ALG3 in vivo.
CONCLUSIONS: Silencing ALG3 plays a critical role in bladder cancer development and growth. It inhibits bladder cancer cells growth in vitro and in vivo.
摘要：
目的：先前的研究表明ALG3与几种癌症有关，但ALG3在膀胱癌（BC）中的功能尚不清楚。目的探讨膀胱癌患者BC组织及相应正常组织中ALG3的相对表达及ALG3相对表达与临床预后的关系。
方法：在本研究中，免疫组化法检测ALG3在膀胱癌中的表达。为了更准确地测定细胞的增殖和迁移能力,我们进行了菌落形成试验,MTT法和伤口愈合迁移法。通过体内动物模型探讨了ALG3在肿瘤生长和转移中的作用。
结果：ALG3在膀胱癌中的表达高于正常组织（P<0.05）。同时,ALG3的表达与预后呈正相关(P<0.05)。此外，我们还发现ALG3的表达与临床病理特征有关（P<0.05）。沉默ALG3可以抑制膀胱癌细胞系T24和5637的增殖和迁移能力。此外,体内沉默ALG3可以抑制膀胱癌细胞系T24细胞的生长。
结论：沉默ALG3在膀胱癌的发展和生长中起关键作用。它在体外和体内抑制膀胱癌细胞的生长。
方法：在本研究中，免疫组化法检测ALG3在膀胱癌中的表达。为了更准确地测定细胞的增殖和迁移能力,我们进行了菌落形成试验,MTT法和伤口愈合迁移法。通过体内动物模型探讨了ALG3在肿瘤生长和转移中的作用。
结果：ALG3在膀胱癌中的表达高于正常组织（P<0.05）。同时,ALG3的表达与预后呈正相关(P<0.05)。此外，我们还发现ALG3的表达与临床病理特征有关（P<0.05）。沉默ALG3可以抑制膀胱癌细胞系T24和5637的增殖和迁移能力。此外,体内沉默ALG3可以抑制膀胱癌细胞系T24细胞的生长。
结论：沉默ALG3在膀胱癌的发展和生长中起关键作用。它在体外和体内抑制膀胱癌细胞的生长。
